CD274 and cancer: Another CD47 targeting bsAB, IBI322, with a dual specificity for CD47 and PD-L1 [122], is also being tested in several clinical trials in patients with advanced malignant tumors (NCT04328831, NCT04912466, NCT04338659) and hematologic malignancies (NCT04795128), but no clinical data has been reported yet.